Malignancies after pediatric kidney transplantation: More than PTLD?

Pediatric Nephrology

Volumn 29, Issue 9, 2014, Pages 1517-1528

  Mynarek, Martin ^a   Hussein, Kais ^a   Kreipe, Hans H ^a   Maecker Kolhoff, Britta ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cancer; Kidney transplantation; Post transplant lymphoproliferative disease; Screening; Transplantation

Indexed keywords

BASAL CELL CARCINOMA; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SCREENING; EARLY DIAGNOSIS; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; MORBIDITY; NON MELANOMA SKIN CANCER; NONHUMAN; PATHOPHYSIOLOGY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SQUAMOUS CELL CARCINOMA; ADVERSE EFFECTS; CHILD; GRAFT REJECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM;

CHILD; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS;

EID: 84898885707     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2622-5     Document Type: Review

References (93)

1. Smith JM, Martz K, Blydt-Hansen TD (2013) Pediatric kidney transplant practice patterns and outcome benchmarks, 1987-2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant 17:149-157
2. Samuel SM, Tonelli MA, Foster BJ, Alexander RT, Nettel-Aguirre A, Soo A, Hemmelgarn BR; Pediatric Renal Outcomes Canada Group (2011) Survival in pediatric dialysis and transplant patients. Clin J Am Soc Nephrol 6:1094-1099
3. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306:1891-1901
4. Simard JF, Baecklund E, Kinch A, Brattström C, Ingvar Å, Molin D, Adami J, Fernberg P, Wilczek H, Ekbom A, Smedby KE (2011) Pediatric organ transplantation and risk of premalignant and malignant tumors in Sweden. Am J Transplant 11:146-151
5. Collett D, Mumford L, Banner NR, Neuberger J, Watson C (2010) Comparison of the incidence of malignancy in recipients of different types of organ: A UK Registry audit. Am J Transplant 10:1889-1896
6. Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, Rigotti P, Busnach G, Messa P, Donati D, Schena FP, Maresca MC, Tisone G, Veroux M, Sparacino V, Pisani F, Citterio F (2013) Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer 49:336-344
7. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE (2006) Cancer incidence before and after kidney transplantation. JAMA 296:2823-2831
8. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F (2003) Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 89:1221-1227
9. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y (2007) Cancer Incidence Among Canadian Kidney Transplant Recipients. Am J Transplant 7:941-948
10. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59-67
11. Cohen AH, Sweet SC, Mendeloll E, Mallory GB, Huddleston CB, Kraus M, Kelly M, Hayashi R, DeBaun MR (2000) High Incidence of Posttransplant Lymphoproliferative Disease in Pediatric Patients with Cystic Fibrosis. Am J Respir Crit Care Med 161:1252-1255
12. Elidemir O, Kancherla BS, Schecter MG, McKenzie ED, Morales DL, Heinle JS, Mallory GB (2009) Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: Recent advances in monitoring. Pediatr Transplant 13:606-610
13. Quintini C, Kato T, Gaynor JJ, Ueno T, Selvaggi G, Gordon P, McLaughlin G, Tompson J, Ruiz P, Tzakis A (2006) Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center. Transplant Proc 38:1755-1758
14. Schober T, Framke T, Kreipe H, Schulz TF, Grohennig A, Hussein K, Baumann U, Pape L, Schubert S, Wingen AM, Jack T, Koch A, Klein C, Maecker-Kolhoff B (2013) Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 95:240-246
15. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr Virus and the origins of associated lymphomas. N Engl J Med 350:1328-1337
16. Höcker B, Fickenscher H, Delecluse H-J, Böhm S, Küsters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schröder M, Billing H, Fichtner A, Feneberg R, Sander A, Köpf-Shakib S, Süsal C, Tönshoff B (2013) Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: A multicenter, prospective study. Clin Infect Dis 56:84-92
17. Chinnock R, Webber SA, Dipchand AI, Brown RN, George JF; The Pediatric Heart Transplant Study (2012) A 16-yearmulti-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients. Am J Transplant 12:3061-3068
18. Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU (2012) Associations Between EBV serostatus and organ transplant type in PTLD risk: An analysis of the SRTR National Registry Data in the United States. Am J Transplant 12:976-983
19. Opelz G, Daniel V, Naujokat C, Dohler B (2009) Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 88:962-967
20. Opelz G, Döhler B (2004) Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4:222-230
21. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE (2001) Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71:1065-1068
22. Opelz G, Dohler B (2010) Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report. Transplantation 90:292-297
23. Manlhiot C, Pollock-BarZiv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan B-Y, McCrindle BW, Dipchand AI (2010) Posttransplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant 29:648-657
24. O'Neill JO, Edwards LB, Taylor DO (2006) Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:1186-1191
25. Funch DP, Ko HH, Travasso J, Brady J, Kew CE 2nd, Nalesnik MA, Walker MA (2005) Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 80:1174-1180
26. Robson R, Cecka JM, Opelz G, Budde M, Sacks S (2005) Prospective registry-based observational sohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5:2954-2960
27. Grinyo J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP (2010) An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 90:1521-1527
28. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RAF, Macon WR, Habermann TM (2006) Post-transplant lymphoproliferative disorders following liver transplantation: Incidence, risk factors and survival. Am J Transplant 6:1017-1024
29. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K (2005) Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80:1233-1243
30. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B (2006) Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 81:1227-1233
31. Chapman TM, Keating GM (2003) Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 63:2803-2835
32. Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ, Potdar S, Shapiro R, Dharnidharka VR, Kauffman HM (2007) Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 7:2619-2625
33. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. World Health Organization, Geneva
34. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076-1088
35. Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 149:693-705
36. Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJ (2012) Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): A Children's Oncology Group report. Am J Transplant 12:3069-3075
37. Bollard CM, Rooney CM, Heslop HE (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9:510-519
38. Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, Hoyer P, Koepf S, Kraemer U, Laube GF, Muller-Wiefel DE, Netz H, Pohl M, Toenshoff B, Wagner HJ, Wallot M, Welte K, Melter M, Offner G, Klein C (2007) CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 25:4902-4908
39. Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, Kirklin JK, Canter CE (2006) Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 367:233-239
40. Jonigk D, Laenger F, Maegel L, Izykowski N, Rische J, Tiede C, Klein C, Maecker-Kolhoff B, Kreipe H, Hussein K (2012) Molecular and clinicopathological analysis of Epstein-Barr virus-associated posttransplant smooth muscle tumors. Am J Transplant 12:1908-1917
41. Mudigonda T, Levender MM, O'Neill JL, West CE, Pearce DJ, Feldman SR (2013) Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single- and multicenter retrospective studies from 2006 to 2010. Dermatol Surg 39:345-364
42. Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, Valerio F, Rugiu C, Sassi F, Gotti E, Fonte L, Talamini G, Girolomoni G (2013) Incidence of primary and second cancers in renal transplant recipients: A multicenter cohort study. Am J Transplant 13:214-221
43. Penn I (1998) De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 2:56-63
44. Euvrard S, Kanitakis J, Cochat P, Claudy A (2004) Skin cancers following pediatric organ transplantation. Dermatol Surg 30:616-621
45. Comeau S, Jensen L, Cockfield SM, Sapijaszko M, Gourishankar S (2008) Non-melanoma skin cancer incidence and risk factors after kidney transplantation: a Canadian experience. Transplantation 86:535-541
46. Arnold AW, Hofbauer GF (2012) Human papillomavirus and squamous cell cancer of the skin-epidermodysplasia verruciformis-associated human papillomavirus revisited. Curr Probl Dermatol 43:49-56
47. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348:1681-1691
48. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GFL, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329-339
49. Hosseini-Moghaddam SM, Soleimanirahbar A, Mazzulli T, Rotstein C, Husain S (2012) Post renal transplantation Kaposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy. Transplant Infect Dis 14:338-345
50. Pedotti P, Cardillo M, Rossini G, Arcuri V, Boschiero L, Caldara R, Cannella G, Dissegna D, Gotti E, Marchini F, Maresca MC, Montagnino G, Montanaro D, Rigotti P, Sandrini S, Taioli E, Scalamogna M (2003) Incidence of cancer after kidney transplant: results from the North Italy transplant program. Transplantation 76:1448-1451
51. Riva G, Luppi M, Barozzi P, Forghieri F, Potenza L (2012) How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood 120:4150-4159
52. Gormley RH, Kovarik CL (2012) Human papillomavirus-related genital disease in the immunocompromised host: Part I. J Am Acad Dermatol 66:867.e1-14; quiz 881-882. doi:10.1016/j.jaad.2010.12.050
53. Pietrzak B, Mazanowska N, Ekiel AM, Durlik M, Martirosian G, Wielgos M, Kaminski P (2012) Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients: an observational study. Virol J 9:117
54. Lee I-S, Kim T-H, Kim Y-H, Yook J-H, Kim B-S, Han D-J (2012) Clinical significance of gastric cancer surveillance in renal transplant recipients. World J Surg 36:1806-1810
55. Au WY, Pang A, Chan EC, Chu KM, Shek TW, Kwong YL (2005) Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology 129:2058-2063
56. Tsaur I, Obermüller N, Jonas D, Blaheta R, Juengel E, Scheuermann E-H, Kachel H-G, Karalis A, Probst M (2011) De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients. BJU Int 108:229-234
57. Debray D, Baudouin V, Lacaille F, Charbit M, Rivet C, Harambat J, Iserin F, Di Filippo S, Guyot C (2009) De novo malignancy after solid organ transplantation in children. Transplant Proc 41:674-675
58. Koukourgianni F, Harambat J, Ranchin B, Euvrard S, Bouvier R, Liutkus A, Cochat P (2010) Malignancy incidence after renal transplantation in children: a 20-year single-centre experience. Nephrol Dial Transplant 25:611-616
59. Hurst FP, Jindal RM, Graham LJ, Falta EM, Ea E, Stackhouse GB, Agodoa LY, Lentine KL, Salifu MO, Abbott KC (2010) Incidence, predictors, costs, and outcome of renal cell carcinoma after kidney transplantation: USRDS experience. Transplantation 90:898-904
60. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA (2011) The epidemiology of renal cell carcinoma. Eur Urol 60:615-621
61. Schwarz A, Vatandaslar S, Merkel S, Haller H (2007) Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc of Nephrol 2:750-756
62. Wong G, Turner RM, Chapman JR, Howell M, Lim WH, Webster AC, Craig JC (2013) Time on dialysis and cancer risk after kidney transplantation. Transplantation 95:114-121
63. Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE, McCredie MRE (2009) The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 24:3225-3231
64. Transplantation EEGoR (2002) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.11 Paediatrics (specific problems). Nephrol Dial Transplant 17[Suppl 4]:55-58
65. Grigoriev Y, Lange J, Peterson SM, Takashima JR, Ritchey ML, Ko D, Feusner JH, Shamberger RC, Green DM, Breslow NE (2012) Treatments and outcomes for end-stage renal disease following Wilms tumor. Pediatr Nephrol 27:1325-1333
66. Querfeld U, Stefanidis CJ (2012) Pediatrics: When should children surviving a Wilms tumor be transplanted? Nat Rev Nephrol 8:443-444
67. Auber F, Jeanpierre C, Denamur E, Jaubert F, Schleiermacher G, Patte C, Cabrol S, Leverger G, Nihoul-Fekete C, Sarnacki S (2009) Management of Wilms tumors in Drash and Frasier syndromes. Pediatr Blood Cancer 52:55-59
68. Patel PR, Pappas J, Arva NC, Franklin B, Brar PC (2013) Early presentation of bilateral gonadoblastomas in a Denys-Drash syndrome patient: a cautionary tale for prophylactic gonadectomy. J Pediatr Endocrinol Metab 9:1-4
69. Beitinjaneh A, Burns LJ, Majhail NS (2010) Solid organ transplantation in survivors of hematopoietic cell transplantation: a single institution case series and literature review. Clin Transplant 24:E94-102
70. Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J (2012) Cancer transmission from organ donors-unavoidable but low risk. Transplantation 94:1200-1207
71. Sener A, Uberoi V, Bartlett ST, Kramer AC, Phelan MW (2009) Living-donor renal transplantation of grafts with incidental renal masses after ex-vivo partial nephrectomy. BJU Int 104:1655-1660
72. Pape L, Lehner F, Blume C, Ahlenstiel T (2011) Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 92:658-662
73. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV (2012) Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 93:73-81
74. Pascual J (2007) Post-transplant lymphoproliferative disorder - the potential of proliferation signal inhibitors. Nephrol Dial Transplant 22:i27-i35
75. Savani BN, Goodman S, Barrett AJ (2009) Can routine posttransplant HPV vaccination prevent commonly cccurring epithelial cancers after allogeneic stem cell transplantation? Clin Cancer Res 15:2219-2221
76. Cohen JI, Fauci AS, Varmus H, Nabel GJ (2011) Epstein-Barr virus: An important vaccine target for cancer prevention. Sci Transl Med 2;3:107fs107. doi:10.1126/scitranslmed.300287
77. Opelz G, Daniel V, Naujokat C, Fickenscher H, Dohler B (2007) Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 8:212-218
78. Ueno Y, Sollano JD, Farrell GC (2009) Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol 24:531-536
79. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F (2009) Meta-analysis: Can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 151:121-128
80. Hathaway JK (2012) HPV: diagnosis, prevention, and treatment. Clin Obstet Gynecol 55:671-680
81. Ulrich C, Jurgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161[Suppl 3]:78-84
82. Wilsdorf N, Eiz-Vesper B, Henke-Gendo C, Diestelhorst J, Oschlies I, Hussein K, Pape L, Baumann U, Tonshoff B, Pohl M, Hocker B, Wingen AM, Klapper W, Kreipe H, Schulz TF, Klein C, Maecker-Kolhoff B (2013) EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease. Transplantation 95:247-255
83. Hinrichs C, Wendland S, Zimmermann H, Eurich D, Neuhaus R, Schlattmann P, Babel N, Riess H, Gärtner B, Anagnostopoulos I, Reinke P, Trappe RU (2011) IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transpl Int 24:892-903
84. Schiffer L, Henke-Gendo C, Wilsdorf N, Hussein K, Pape L, Schmitt C, Haller H, Schiffer M, Klein C, Kreipe H, Maecker-Kolhoff B (2012) CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD. Am J Transplant 12:1610-1617
85. Haque T, Chaggar T, Schafers J, Atkinson C, McAulay KA, Crawford DH (2011) Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol 83:311-316
86. Harwood CA, Mesher D, McGregor JM, Mitchell L, Leedham-Green M, Raftery M, Cerio R, Leigh IM, Sasieni P, Proby CM (2013) A surveillance model for skin cancer in organ transplant recipients: A 22-year prospective study in an ethnically diverse population. Am J Transplant 13:119-129
87. Pietrzak B, Bobrowska K, Szpotanska-Sikorska M, Jabiry-Zieniewicz Z, Kociszewska-Najman B, Durlik M, Kaminski P, Wielgos M (2011) Multiple types of high-risk human papilloma virus in the lower genital tract of a female kidney recipient: A case report. Transplant Proc 43:2994-2996
88. Ishikawa I, Honda R, Yamada Y, Kakuma T (2004) Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial 8:468-473
89. Pinho-Apezzato ML, Tannuri U, Tannuri ACA, Mello ES, Lima F, Gibelli NE, Santos MM, Ayoub AA, Maksoud-Filho JG, Velhote MC, Silva MM, Andrade WC, Miyatani HT (2010) Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: A single-center experience. Transplant Proc 42:1763-1768
90. Dharnidharka VR, Martz KL, Stablein DM, Benfield MR (2011) Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am J Transplant 11:751-758
91. Orjuela MA, Alobeid B, Liu X, Siebert AL, Kott ER, Addonizio LJ, Morris E, Garvin JH, Lobritto SJ, Cairo MS (2011) CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. Br J Haematol 152:733-742
92. Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, Morelon E, Moal V, Janbon B, Alamartine E, Pouteil Noble C, Morel D, Kamar N, Buchler M, Mamzer MF, Peraldi MN, Hiesse C, Renoult E, Toupance O, Rerolle JP, Delmas S, Lang P, Lebranchu Y, Heng AE, Rebibou JM, Mousson C, Glotz D, Rivalan J, Thierry A, Etienne I, Moal MC, Albano L, Subra JF, Ouali N, Westeel PF, Delahousse M, Genin R, Hurault de Ligny B, Moulin B (2013) Posttransplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol 31:1302-1309
93. Tiede C, Maecker-Kolhoff B, Klein C, Kreipe H, Hussein K (2013) Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. Transplantation 95:479-488